M&A Deal Summary

Roche Acquires 454 Life Sciences

On March 29, 2007, Roche acquired life science company 454 Life Sciences from CuraGen for 140M USD

Acquisition Highlights
  • This is Roche’s 2nd transaction in the Life Science sector.
  • This is Roche’s 25th largest (disclosed) transaction.
  • This is Roche’s 1st transaction in the United States.
  • This is Roche’s 1st transaction in Connecticut.

M&A Deal Summary
Date 2007-03-29
Target 454 Life Sciences
Sector Life Science
Buyer(s) Roche
Sellers(s) CuraGen
Deal Type Divestiture
Deal Value 140M USD

Target

454 Life Sciences

Branford, Connecticut, United States
454 Life Sciences develops and commercializes novel instrumentation for high-throughput DNA sequencing. Specific applications include whole-genome sequencing, RNA analysis and ultra-deep sequencing of target genes. The hallmarks of 454 Sequencing are its simple, unbiased sample preparation and massively parallel sequencing, which makes large-scale scientific projects feasible and more affordable.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 4 of 42
Sector (Life Science) 2 of 29
Type (Divestiture) 1 of 3
State (Connecticut) 1 of 1
Country (United States) 1 of 28
Year (2007) 1 of 3
Size (of disclosed) 25 of 29
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2005-07-19 GlycArt Biotechnology AG

Zurich, Switzerland

GlycArt is a Swiss biotechnology company focussed on the development and commercialisation of a new generation of antibody products based on its proprietary GlycoMAb technology. GlycArt has generated its own GlycoMAb-based antibody portfolio by in-licensing and acquiring antibodies at early stages of development and applying GlycoMAb to them.

Buy Fr.235M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-06-19 NimbleGen Systems

Madison, Wisconsin, United States

NimbleGen Systems is an innovator, manufacturer and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. NimbleGen uniquely produces high-density arrays of long oligo probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation.

Buy $273M

Seller(S) 1

SELLER

CuraGen

Branford, Connecticut, United States
Category Company
Sector Life Science
DESCRIPTION

CuraGen Corporation has a portfolio of 11 fully-owned, human antibodies that the Company selected, optimized and advanced during its collaboration with Abgenix (acquired by Amgen). CR011, currently in Phase 2 studies, is an antibody-drug conjugate that targets GPNMB, a protein that is highly expressed in metastatic breast cancer and melanoma. CR011 has shown promising early evidence of anti-tumor activity, including objective tumor responses, in patients with breast cancer and unresectable stage III and IV melanoma.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Connecticut) 1 of 1
Country (United States) 1 of 1
Year (2007) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal